Determinants of vascular function in patients with chronic gout
- PMID: 21366849
- PMCID: PMC3076024
- DOI: 10.1111/j.1751-7176.2010.00406.x
Determinants of vascular function in patients with chronic gout
Abstract
Epidemiologic studies have proposed a relationship between hyperuricemia and cardiovascular (CV) risk. However, it is unclear whether uric acid (UA) is an independent risk factor for CV disease (CVD) after controlling for other predisposing conditions. Gout patients might have persistent systemic inflammation, which, in addition to hyperuricemia, may potentiate CVD. This study examined vascular function and markers of CV damage in gout patients when compared with healthy controls. Brachial artery flow-mediated dilatation, arterial compliance, and microvascular function were measured. Circulating apoptotic endothelial cells and endothelial progenitor cells were quantified by FACS and circulating biomarkers of CVD by enzyme-linked immunosorbent assay. Gout patients displayed significant increases in body mass index, C-reactive protein, UA, and triglycerides and decreases in high-density lipoprotein. There were no significant differences in other CV traditional risk factors, adhesion molecules, or chemokines. Gout patients did not differ from controls in vascular function. In univariate and multivariate analysis, UA was not associated with the quantified CV risk parameters. Despite an increase in several CV risk factors, inflammation, and UA, gout patients display normal endothelial function and no increases in biomarkers of CVD. These results do not support the notion that gout is an independent risk factor for premature CVD.
© 2010 Wiley Periodicals, Inc.
Similar articles
-
Detrimental role of hyperuricemia on the cardio-reno-vascular system.Curr Med Res Opin. 2015;31 Suppl 2:21-6. doi: 10.1185/03007995.2015.1087984. Curr Med Res Opin. 2015. PMID: 26414733 Review.
-
Hyperuricemia, gout, and cardiovascular disease--an important "muddle".Bull NYU Hosp Jt Dis. 2009;67(3):285-90. Bull NYU Hosp Jt Dis. 2009. PMID: 19852752 Review.
-
Inflammation: a possible mechanism for a causative role of hyperuricemia/gout in cardiovascular disease.Curr Med Res Opin. 2015;31 Suppl 2:9-14. doi: 10.1185/03007995.2015.1087980. Curr Med Res Opin. 2015. PMID: 26414731 Review.
-
Coexistent Hyperuricemia and Gout in Rheumatoid Arthritis: Associations With Comorbidities, Disease Activity, and Mortality.Arthritis Care Res (Hoboken). 2020 Jul;72(7):950-958. doi: 10.1002/acr.23926. Epub 2020 Jun 7. Arthritis Care Res (Hoboken). 2020. PMID: 31074584 Free PMC article.
-
Beyond gout: uric acid and cardiovascular diseases.Curr Med Res Opin. 2013 Apr;29 Suppl 3:33-9. doi: 10.1185/03007995.2013.790804. Epub 2013 Apr 24. Curr Med Res Opin. 2013. PMID: 23611366 Review.
Cited by
-
Serum uric acid still carries controversies about its role in endothelial dysfunction.J Clin Hypertens (Greenwich). 2013 Apr;15(4):296. doi: 10.1111/jch.12066. Epub 2013 Feb 1. J Clin Hypertens (Greenwich). 2013. PMID: 23551731 Free PMC article. No abstract available.
-
Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis.Eur J Prev Cardiol. 2015 Mar;22(3):335-43. doi: 10.1177/2047487313514895. Epub 2013 Nov 26. Eur J Prev Cardiol. 2015. PMID: 24281251 Free PMC article. Review.
-
Interleukin 17 as a novel predictor of vascular function in rheumatoid arthritis.Ann Rheum Dis. 2011 Sep;70(9):1550-5. doi: 10.1136/ard.2010.148031. Epub 2011 Jul 4. Ann Rheum Dis. 2011. PMID: 21727237 Free PMC article.
-
Impact of Hyperuricemia and Urate-Lowering Agents on Cardiovascular Diseases.Clin Med Insights Cardiol. 2024 Mar 24;18:11795468241239542. doi: 10.1177/11795468241239542. eCollection 2024. Clin Med Insights Cardiol. 2024. PMID: 38529322 Free PMC article. Review.
-
Gout and Metabolic Syndrome: a Tangled Web.Curr Rheumatol Rep. 2017 Aug 26;19(10):60. doi: 10.1007/s11926-017-0688-y. Curr Rheumatol Rep. 2017. PMID: 28844079 Review.
References
-
- Baker JF, Krishnan E, Chen L, et al. Serum uric acid and cardiovascular disease: recent developments, and where do they leave us? Am J Med. 2005;118(8):816–826. - PubMed
-
- Hoieggen A, Alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int. 2004;65(3):1041–1049. - PubMed
-
- Wen CP, David Cheng TY, Chan HT, et al. Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk. Am J Kidney Dis. 2010;56(2):273–288. - PubMed
-
- Iribarren C, Folsom AR, Eckfeldt JH, et al. Correlates of uric acid and its association with asymptomatic carotid atherosclerosis: the ARIC Study. Atherosclerosis risk in Communities. Ann Epidemiol. 1996;6(4):331–340. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials